academic-nhs-industry collaboration in experimental medicine

7/30/2019 Academic-NHS-Industry Collaboration in Experimental Medicine

1/20

Academic NHS Industry Collaborationin Experimental Medicine

Innovative partnering

Office for Clinical Research Infrastructure


2/20

Contents

3 Foreword

5 Benetsofcollaboration

6 Collaboration1:NIHRNationalCancerResearchNetwork-AstraZeneca Early-stagedrugdevelopment

8 Collaboration2:TheUniversityofCambridge-GlaxoSmithKline AnAcademicDiscoveryPerformanceUnit

10 Collaboration3:NIHRBiomedicalResearchCentre,MooreldsEyeHospitalNHSTrust- UniversityCollegeLondon-TheAutomationPartnership

Regenerativemedicineapplicationsinophthalmology

12 Collaboration4:NIHRBiomedicalResearchCentre,NewcastleUniversity-Multiple IndustryPartners

Acollaborativetrainingprogrammeintranslationalresearch

14 Collaboration5:TheUniversityofBrighton-TheBrightonandSussexUniversityHospitals NHSTrust-NeaterSolutions

Improvedassistedlivingtechnology

16 Collaboration6:TheUniversityofEdinburgh-NHSLothian-Pzer Generationofawell-characterisedpatientcohort

18 Appendix

19 PostscriptfromtheManagingDirectoroftheNIHROfceforClinicalResearch Infrastructure(NOCRI)


3/20

3

Foreword

Innovativepartneringcanacceleratethe

developmentofnewtreatments,devices

anddiagnosticstotacklecomplex

healthcareneeds.Creativeengagement

betweentheNHS,universitiesand

industryformsapowerfulalliancetodrive

translationalmedicineintheUK.This

allianceisvital.Itensuresthatadvancesin

basicscienceprogressswiftlyintobenets

forpatientsandtheeconomy.

TheNationalInstituteforHealthResearch

andMedicalResearchCouncilhave

compiledthisbookletinordertosharesix

examplesofinnovativeresearchthatinvolve

successfulpartneringbetweentheNHS,

universitiesandindustry.Theseexamples

showdifferentsortsofcollaboration,

supportedbyarangeoffunders.

Avarietyofapproacheshavebrought

aboutsuccessfulcollaborations.Many

involveacommitmentofmaterial,funding

orexpertise.Industryhasbeenwillingto

shareuniquecompoundlibraries.Shared

risk-rewardmodelshavebeencreatedto

fundprogrammesofwork.Training

programmes,secondmentsandjointposts

havehelpedshareexpertiseandbestpractice.

Wehopethatreadingtheseexampleswill

inspireyoutoexploreideasforcollaboration

adaptedtoyourownareaofinterest.

Professor Dame

Sally C. DaviesDirectorGeneralofR&D,

DepartmentofHealth

Professor Sir

John SavillChiefExecutiveof

theMRC


4/20

4

Benetsofcollaboration

Theabilityofacademia,theNHSand

industrytocollaborateinmoreproductive

wayswillspeedtranslationofscienticideas

andobservationsintotherapeuticsand

benetsforpatients.

Collaborationiseffectivewhenitteams

complementaryscienticskills,knowledge

andtechnologiestotackleacomplex

researchissue.Itismostpertinentwhen

undertakingtheearlyclinicalphaseinthe

developmentofanewhealthcareproduct.

Atarecentworkshopinvolvingthedirectors

ofacademicexperimentalmedicinecentres

andindustryscientists,anumberof

complementarystrengthsandresources

werehighlighted:

Thepharmaceutical,biotechnologyand

medicaltechnologyindustriescould

adoptmoreinformedapproachesto

drug,deviceanddiagnosticdesignand

developmentthroughcollaboration.UK

academiahostsastrongcohortof

investigatorswithinnovativediscoveries

andideasarisingfromdetailed

explorationsofspecicdiseases.

Accuratediseasebiomarkersdeveloped

andvalidatedbyacademiacanimprove studyprotocols,stratifypatient

populationsandultimatelyensure

therapydevelopmentismoretargeted

andefcient.

PartneringwiththeUKsworldclassNHS,

includingitsclinicians,healthcare

professionalsanddedicatedexperimental

medicineresearchinfrastructure,fosters

engagementwithpatientsandtheir

carers.Operatinginthecontextofa

uniedcaresystemensuresproduct

designisbetterinformedandpotentially

stratiedbypatientdisease.

Earlyaccesstoindustrycompoundsand

technologiespresentsacademicsand

clinicianswiththeopportunityforunique

rst-in-humanclinicalresearchstudies.

Theseprovideaplatformforfurther

researchanddevelopment,aswellas

expandtheknowledgebaseand

publicationrecord.Industrycanalso

shareitswealthofexperiencein

negotiatingtheregulatorypathwaysto

rst-in-humanstudies.


5/20

5

Withintranslationalmedicine,stronger

collaborationbetweenuniversities,the

NHSandindustrywillbecomeapowerful

platformforengagingandinuencingother

importantstakeholders,suchasnationaland

internationalregulatoryauthorities.

Personalcontacts,showcases,workshops

andconferencesremainfertilegroundfor

initiatingcollaboration.Researchfunders

providearangeofsupportbothforevents

tokick-startpartneringandthrougha

varietyoffundingstreamstosupport

collaborationsatalllevels,fromindividual

projectstolargescaleconsortia.Themodel

IndustryCollaborativeResearchAgreement

(mICRA),streamlinedregulatoryapprovals

andguidancewithroutemapsfor

intellectualpropertyagreementsallaimtosimplifypartnering.

AgainstabackdropofhighratesofphaseII

candidatecompoundattrition,andan

increasingemphasisonopeninnovation

bythelifesciencesindustries,thetimeis

ripetoencourageearlystagecollaboration

betweenindustry,academiaandtheNHS.


6/20

InitiatedbyachancediscussionbetweenProfessorDavidCameronoftheNIHRNationalCancer

ResearchNetwork(NCRN)andProfessorAndrewHughesofAstraZeneca(AZ),thiscollaboration

offeredmutualbenets.AZwerelookingtoevaluatetheircompoundsinabroaderrangeofcancers,

andtheNetwork(comprisingmultipleclinicalinvestigators)wouldgainaccesstonovelmolecules

forimprovedoncologyresearchandpatientbenet.

Offer

Collaborative functions

Outcome

6

R&Dofdrugsforcancersoutsidecompanyscoreprogramme

Earlierpatientaccesstonewandmoreinnovativedrugs

14PhaseIIClinicalStudies

Anestablishedmodelofcollaborativeworkingthatcouldbe

rolledoutinotherdiseaseareasandwithother industrypartners

Jointprotocolsign-off

Early-stagedatasharing

Collaborativechoiceofleadcandidatemolecules

Systematiccollaborativesupportincludingmodelagreements

Combinationaltherapeuticapproaches

Researchinfrastructure

NHSpatientaccess

Novelprotocoldevelopment Objectivemoleculeevaluation

Integrateddiseaseknowledge

Denedcollaborationbudget

Portfolioofnovelmolecules

Patientsupportcosts Drugdevelopmentexpertise

ProfessorsRickKaplan&DavidCameron

(NCRN)broughtpreviousexperienceofindustry

engagementfromtheNationalCancer

Institute,USA.

ProfessorAndrewHughes,aseniorVPatAZ,

heldajointpositionasChairofTranslational

MedicineattheUniversityofManchesterand

hadenthusiasmforworkingwithacademia.

InitiationAcademia Industry


7/20

7

Keysuccessfactors

Accesstoandengagementof

AstraZenecadecisionmakersin

thecompanysUKCancerDivision

Headquarters

Effectiveworkshopsinvolvingindustry

product&diseaseteamsandacademic

studygroupsgeneratedideasand

opportunitiesforthedevelopmentof

drugcandidates

Long-termsupportforthecollaboration

wasestablishedintheformofmodel

contracts,clearrolesandresponsibilities, activemanagementandorganisational

understanding

Youneedtosimplysitdownwithcompanies

andndcommonareas.Perhapslookat1or2

moleculesanddiseaseareaswhereacompany

maywishtobroadentheiractivity.Emphasise

theneedforlong-termcollaborationandestablishthesystemstoensurethis.

Thisreallyisawin-winsituation.Wecan

providedataaboutourdevelopmentpipeline

andcompoundsthatallowacademicresearchers

topursueinterestingareasofscience,whilstwe

gainavitalexternalperspective,andresearchdatathatmaypointtowardsnewindicationsfor

aparticulardrug.

Professor Rick Kaplan

AssociateDirectorof

theNationalCancer

ResearchNetwork

Chris Wilks

CoordinationDirector

&HeadofPartnerships,

AstraZeneca


8/20

CambridgeUniversity,CambridgeUniversityHospitalsNHSTrustandGlaxoSmithKlinehavebuilt

uponastronghistoryofcollaboration.AsaGSKAcademicDiscoveryPerformanceUnit,Cambridge

academicsworkasstakeholdersontheclinicaldevelopmentofproprietaryGSKdrugcandidates,while

GSKgainthecross-themedexpertiseofinternationalexperts.

Initiation

Offer


Outcome

Academia Industry

Onecandidatedrugforobesitysuccessfullyprogressedthrougha

phaseIprogrammeandisnowundergoingphaseIItrials.

Preclinicalstudiesonacandidatedrugbeinganalysedprimarilyfor

obesityhaveidentiedanadditionaltherapeuticactivityforaddiction

Agreaterappreciationoftheissuesfacingthetwopartnershas

broughtacademiaandindustrycloserinthissetting

Embeddedacademicteams

Programme-levelagreementstocoverIP,publicationrights,

andotherrulesofengagement

Asharedrisk-rewardstructure

Projectmanagementfocusedon

delivery

Structuralandstrategicmodelof

aGSKprojectteam

Specialistdrug-development knowledge

Commercialanalysis

Non-compartmentalisedand

imaginativethoughttoaresearch

questionthatcutacrosstwoGSK

diseaseteams,neuroscienceand

metabolism

Objectivejudgementofacandidate

drugspotential

ThesecondmentofProfessorEdBullmorefromCambridgetoworkhalf-timeasheadoftheGSK

CambridgeClinicalUnit,basedinAddenbrookesHospital,greatlyfacilitatedthiscollaboration.BuildingonafoundationofpreviousCambridge-GSKpre-competitivecollaboration,therewasa

mutualdesireforgreateracademicinputintheclinicaldevelopmentactivitiesofGSK.

8


9/20

9

Keysuccessfactors

Anapproachthatprioritisedscientic

engagementasanincentiveforindividual

academics

Financialrisk-sharingmodel

TheonsiteGSKclinicalunitin

Cambridgehelpedtobuildbridgesand

enablethepartnerstorealiseeach

othersvaluetothecollaboration

Cambridgeacademicssuccessfully

presentedanorganised,coherentand

compellingoffertoGSKinatherapeutic

areainwhichtheyexcelledinan

internationalcontext

Adrivingforcebehindthiscollaborationwas

therealisationthattheexistingGSKunitonthe

Cambridgecampuswasnotinitselfenoughto

establishstrongcollaborations.Therehadtobe

anarrangementthatallowedacademicstobeincontrolofthedrugdevelopmentworkinorder

tomotivatethemonascienticlevel.

Professor Ed BullmoreCambridgeUniversity/

GSK

ThiscollaborationwithCambridgehashad

averypositiveeffectonGSKscientists.The

innovativenatureofthecollaborationhas

stimulatedmoreinnovativethinkingfromour

teamsandliberatedtheiracademicwithin.

Dr Pauline Williams

HeadofGSKsAcademic

DiscoveryPerformance

Unit,Cambridge


10/20

Amethodforgrowingtransparenttissue,developedbyacademicsatUniversityCollegeLondon(UCL),

waslicensedtoTheAutomationPartnership.CollaborationwiththeNIHRBiomedicalResearchCentre

(BRC)atMooreldsEyeHospitalbroughttherapeuticapplicationstocureblindnessthroughtheproposed

generationofacompleteocularsurface.Thetechnologyultimatelyhasapplicationsinmanyareasof

regenerativemedicine.

Initiation

Offer


Outcome

Academia Industry

10

ProfessorRobertBrownofUCLpatentedtechnologies

formembranessupportingcellgrowth.DrJulieDanielsoftheNIHRBRCatMooreldsjoinedthe

TechnologyStrategyBoard-fundedcollaboration

todevelopclinicalapplicationsforthetechnology

inoculartherapy.

TheAutomationPartnershipwereinterested

inlicensingthistechnologyforcommercialdevelopment,andwereawardedagranttothis

endfromtheTechnologyStrategyBoard(TSB).

Experienceinautomatedcell

culturesystems

Robustprotocolsandtechnique

standardisation

Funding

LeadapplicantontheTechnology

StrategyBoardgrant

Translationalresearchexpertise

intheeldofoculartherapy

Patentedtechnologies

Academiccontactsinfurther therapeuticareas

NIHR-fundedresearchinfrastructure

TheAutomationPartnershipwonacollaborativegrant

fromtheTechnologyStrategyBoard

Appropriatepatentsareledinopennegotiationbetween

thepartners

Twentyindividualsfrombothacademiaandindustryare

involvedintheproject

Apatentedautomatedworkstationcapableofproducing

consistent3Dtissuestructures

Publicationsandconferencepresentationsfromboth

academicandindustrypartners

Grantapplicationssubmittedforspin-offprojectsinfurther

areasofregenerativemedicine


11/20

Keysuccessfactors

Enthusiasmandcommitmentofthe

partnerstowardsacommongoal

Availabilityofcollaborativefunding

tokickstartdevelopmentofa

commerciallyhigher-risktechnology

Aprotectedacademicideadeveloped

bycommercially-awarescientists

ACollaborationSteeringCommittee

toquicklyescalateissuesandkeepthe

projectontrack

ThecelltherapyunithostedbytheNIHR BiomedicalResearchCentreatMoorelds

Adeeprelationshiphasdevelopedbetweenthe

collaboratorsandmuchhasbeenlearntinthe

eldoftissueengineeringfromworkingwith

world-classresearchers.Thesuccessesalready

realisedinthisprojectwouldsimplynothavebeenseenoutsideofthiscollaborativemodel.

Dr Rosemary Drake

ChiefScienticOfcer,

TheAutomation

Partnership

Theestablishmentofcoreinfrastructureinthe

formoftheNIHRBRCscelltherapyunitwas

crucialinattractingTheAutomationPartnership

tospecicallyentertheareaofcorneal

regeneration.Theprojecthasreallybenetedfromtheexpertiseoftheindividualsinthisunit.

Dr Julie DanielsReader,NIHRBRC,

MooreldsEyeHospital

11


12/20

TheWellcomeTrusthassupportedatrainingprogrammedevelopedcollaboratively

betweenNewcastleUniversityandseveralindustrypartners.Ithasprovenverypopularwith

bothclinicalfellowsandindustry,andactedasacatalystforgreaterindustryengagement

atNewcastle.

Initiation

Offer


Outcome

Academia Industry

Therewasamutualrealisationbetweenindustryandacademiathat,althoughmanypeople

discussedthetopicoftranslationalresearch,fewwithinacademiaactuallyunderstoodhow

toeffectivelydeveloptheresultsofresearchintotherapiesandtechnologiesforpatientbenet.

UpdatedRealWorldcourse

content

PhDprogrammesintranslational

researchhostedatindustrysites

Expertexperienceintherapy

development

NIHRBiomedicalResearchCentre

withdedicatedinfrastructure

fundingtosupportresearch

translation

Anexperiencedgroupofclinical

academics

NewcastleUniversityengagedmultipleindustrypartners

CollaborativedevelopmentofarstyearMasterscourse

entitledMResinMedicalandMolecularBiosciences

Partnersagreedtouserealexperimentaldatatoenrichthecoursecontent

University,NHSandindustrypartnersfoundthemselveson

thesamesideofthetablewhendesigninganddelivering

thetrainingprogramme

University-NHS-industryinteractionsinNewcastlearemore

common,richanddiverseasaresultofthiscollaboration

12


13/20

Key success factors

Seniorindustryguresfromthepartner

companiesworkalongsideacademicsto

delivertheMastersprogramme

Astrongtranslationalresearch

environmentwithintheNewcastle

NIHRBiomedicalResearchCentre

Thecoursetacklesaveryrealgapin

translationalknowledgewithinthe

clinicalacademiccommunity

Broadprolesofthecompaniesinvolved,

whichincludeSano-aventis,Roche,

AstraZeneca,PTCTherapeutics,Sirtris

andGSK

Thesuccessofthecoursehasmeantthatwe

areontargetforittobeself-fundingwithinthe

planned5yeartimescale.Therearebigplansto

rollmodulesoutnationwideinspecicdisease

areas,ortoaidincontinuingprofessionaldevelopmentforindustryproles.

Professor David Jones

NewcastleNIHR

BiomedicalResearch

Centre

13

Collaborativetranslationalmedicineprogrammes

provideauniqueopportunityforearlystage

researchtoprogressandtransitionintoadvanced

development.Inthenearterm,programmesin

translationalmedicinewillbenetbothacademiaandindustry.Lookingtothefuture,

globalhealthcareandoverallqualityoflifewill

bethebeneciaries.

Dr Zvi LoewyVicePresidentof

ResearchforDentalCare

atGlaxoSmithKline


14/20

Thecollaborativedevelopmentofthiswheelchair,involvingacademicsatBrightonUniversity,NHS

cliniciansandtheirpatientsandengineersatNeaterSolutionsofferspatientsmorefreedomthanthe

standardNHSwheelchair.AcrucialgrantwasawardedfromtheNationalInstituteforHealthResearch

(NIHR)HealthTechnologyDevicesProgramme.


Outcome

Offer

InitiationAcademia Industry

14

Commercialacumen

Engineeringdesignexperience

Productionfeasibility

IPownershipandpublicationissueswereaddressedatthe

beginningofthecollaboration

ThetriallingofprototypesinNHSpatientshomeswascrucial

toresolveearly-stagedesignproblems

Openchannelsofcommunicationweremaintainedand quarterlymeetingsheldbetweenthecollaborators

EngineerSamuelLesleybegandevelopingthe

foot-steeredwheelchairduringastudentproject.In2002heapproachedDrAnneMandyatthe

UniversityofBrightonwiththeidea.

JonMichaelis,ManagingDirectorofNeater

Solutions,signeduptodevelopthetechnologyinacollaborativedealwiththeacademicpartners.

Theinvolvementofrehabilitation

teams,carehometeamsandstroke

professionals

Effectivepatientengagement

Grantapplicationexpertise Trialprotocoldesign

Theproducthasbeenshowcasedatinternational

conferencesandexhibitions

Thereputationsofallpartnersbenettedfromanumber

ofpublications

NeaterSolutionsarelookingtoengagewithotheracademic

partnersinotherdeviceareasasaresultofthiswork


15/20

Keysuccessfactors

Datawerepublishedfromwelldesigned

trialsthatdemonstratedthebenetsof

thedesignoverstandardwheelchairs.

Thiswaskeytosecuringfurthergrant fundingfortheproject

Extensivepatientandcarerinvolvement

foreachtrialandfurtherengagementvia

newsletters

Strongcoverageofprogressthrough

scienticpublications,conference

presentations,localpresscoverage

andpatientcomment

Clearareasofleadershipand

responsibilitywereestablishedin

thecollaboration

Followingtrialsoftheprototype,itwasvital

thatacommercialpartnerwasengagedinorder

toattractfurtherfunding.TheNIHRHealth

TechnologyDevicesprogrammebecame

availabletousandlaunchedthenextphaseofdevelopment.

Dr Anne MandyUniversityofBrighton

Workingwithacademiawascrucialtosecure

grantsforthedevelopmentwork.Italsoensured

ourdesignoptimallymettheneedsofboth

patientsandcarers.Forinstance,trialsinpatients

homestriggeredadesignchangeinthesteeringsystemthatwasnotpredictedatthestartofthe

project.Futurestudiesintotheimpactonpatient

healthandcarewillbeimportanttosecurefunding

oftheequipmentfortheindividualswhoneedit.

Jon Michaelis

ManagingDirector,

NeaterSolutions

15


16/20

Thiscollaborationevolvedfromanacademically-ledcohortstudyinvestigatingthecomplicationsof

diabetesinolderpatients.Pzersinvolvementsignicantlyexpandedtherangeofbaselineinformation

collectedontheparticipants,exploredbiomarkersandprovidedaplatformforbroaderstudies.

Initiation

Offer


Outcome

Academia Industry

16

AnMRC-fundedstudywascollectingclinicaldataoninammationandmicrovasculardiseaseinolder

diabetespatientswithafocusonthedevelopmentandprogressionofcognitiveimpairment.Achancediscussionbyoneoftheclinicalco-investigatorswithhislocalareadrugrepresentativestirredinterest.

Pzerwereinterestedinopportunitiesforcomplementaryinvestigationsonliverdysfunction,another

complicationofdiabetes.

Interestinliverfunctionindiabetes

Funding

Specialistbiomarkermethodologies

Multidisciplinaryteam

Protocoldesign

Cohortof1000seniordiabetic

patients Dedicatedresearchinfrastructure

Expandedbiomarkerinvestigationsonparticipantsallowinga

morecomprehensiveunderstandingofdiabeticcomplications

Comparisonofdifferentmeasurementtechniques

Crossvalidationofnovelbiomarkers

Anintensivelyphenotypedcohort

Expandeddatasetsgivingastrongplatformforfuturestudies

onasuiteofdiabeticcomplications

Publicationsandconferencepresentations

Validatedtechniquestobeusedforfuturedatacollection

Asolidplatformforfuturegrantsubmissions


17/20

Keysuccessfactors

Amultidisciplinaryacademicteam

Topclassresearchinfrastructure

UK-basedleadscientistatPzer

Alignmentofourinterestswiththatof

Industrialpartnerswasvaluable.Italsohelped

havingakeypersonhereintheUKtotalkto

andbuildamorepersonalworkingrelationship,

assometimescollaborationatadistancecanbedifcult.

Dr Jackie Price

ClinicalSeniorLecturer

inEpidemiologyand

PublicHealth,The

UniversityofEdinburgh

17

FromaPzerperspective,accesstoawell

phenotypedpatientcohortwaskey.Itisoften

verydifculttobeabletoaccesslongitudinal

dataandclinicalsamplesthatwillallowa

betterunderstandingofdiseaseemergenceandprogression.

Dr Geoff Johnston

DirectorofMolecular

Medicine,Pzer


18/20

18

Appendix

Usefullinks:

Medical Research Council (MRC)

IndustryCollaborationAward(MICA)

www.mrc.ac.uk/Fundingopportunities/Grants/MICA/Specication/index.htm

National Institute for Health Research (NIHR)

InventionforInnovationProgramme(i4i)

www.nihr-ccf.org.uk/site/programmes/i4i/

Technology Strategy Board (TSB)

CollaborativeResearchandDevelopment

www.innovateuk.org/deliveringinnovation/collaborativeresearchanddevelopment.ashx

The Wellcome Trust

Collaborativetranslationalfundingstreams

www.wellcome.ac.uk/Funding/index.htm

UKCRC Experimental Medicine Resources Website

OnlinedatabaseoftheUKsexperimentalmedicineinfrastructureandexpertise

www.ukcrcexpmed.org.uk


19/20

Thisbooklethighlightssixinnovativemodels

ofearlyphasepartnershipsbetweenindustry,

theNHSanduniversities.Theseshowa

varietyofwaysbywhichcollaborations

canarisetobenetallparties.

Anumberofthecollaborationsbuildupon

previouslyestablishedrelationships.Others

beganfromchanceinteractionsorpersonal

relationships.TheNIHROfceforClinical

ResearchInfrastructure(NOCRI)aimsto

makethisprocessmorestreamlinedby

linkingindustrywiththecountrysleading

academicexperimentalmedicineexpertsin

acoordinatedway,aswellasbyprovidinga

forumforearlycollaborativediscussions.

Additionally,NOCRIisprovidingthetools

tosupporttheseinteractions.Forexample,

therecentlydevelopedmodelIndustry

CollaborativeResearchAgreement(mICRA)

canshortenthecontractingprocessfor

collaborativerelationships.Ifyouwouldlike

toknowmoreabouthowNOCRIcanhelp

youtoestablishacademic-NHS-industry

collaborations,pleasecontactusat:[email protected].

19

PostscriptfromtheManagingDirectoroftheNIHROfce

forClinicalResearchInfrastructure(NOCRI)

Forfurtherinformationorsupportwithresearch

collaborations,contact:[email protected]

MarkSamuels,

ManagingDirector,NOCRI


20/20

NIHROfceforClinicalResearchInfrastructure(NOCRI)

132RichmondHouse

79Whitehall

London

SW1A2NS

www.nihr.ac.uk/nocri

Tel: +44 (020) 7210 6217

MRCHeadOfce(London)

14thFloor

OneKembleStreet

London

WC2B4AN

www.mrc.ac.uk

Tel: +44 (0)1793 416 200

academic-nhs-industry collaboration in experimental medicine

Documents